Typical changes in the lungs of children with COVID-19, atypical treatment


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Center for Children’s Health, which required intensive treatment, but in some cases the course of this infection did not require a specific approach in the presence of significant changes in the lungs. Based on updated world data and our own experience, the Clinic has made changes to the treatment protocols for children with moderate to severe COVID-19, including a short course of systemic glucocorticosteroids, as well as low molecular weight heparin. The success of this approach was the starting point for its inclusion in the new, second version of the guidelines for the treatment of COVID-19 in children dated 07/03/2020.

Full Text

Restricted Access

About the authors

A. S Polyakova

National Medical Research Center for Children's Health

Email: darmanyan@nczd.ru
Cand. Sci. (Med.), Pediatrician, Department of Diagnostics and Rehabilitation Treatment

M. D Bakradze

National Medical Research Center for Children's Health

I. L Mityushin

National Medical Research Center for Children's Health

I. L Chashchina

National Medical Research Center for Children's Health

A. A Tkacheva

National Medical Research Center for Children's Health

References

  1. Sheng-Ta Tsai, Ming-Kuei Lu, Shao San, Chon-Haw Tsai. The Neurologic Manifestations of Coronavirus Disease 2019 Pandemic: A Systemic Review. Front Neurol. 2020;11:498. Published on-line 2020 May 19. Doi: 10.3389/ fneur.2020.00498.
  2. Soy M., Keser G., Atagündüz P., et al. Cytokine Storm in COVID-19: Pathogenesis and Overview of Anti-Inflammatory Agents Used in Treatment. Clin Rheumatol. 2020;39(7):2085-94. doi: 10.1007/s10067-020-05190-5.
  3. Ferranti J.F., Rodriguez I.S., Motta E., et al. Beyond ventilatory support: challenges in general practice and in the treatment of critically Ill children and adolescents with SARS-CoV-2 infection. Rev Assoc Med Bras. 2020;66(4):521-27. doi: 10.1590/1806-9282.66.4.521.
  4. He F., Deng Y., Li W. Coronavirus disease 2019: What we know? J. Med Virol. 2020. doi: 10.1002/jmv.25766.
  5. Carlotti A.PC.P., de Carvalho W.B., Johnston C., et al. COVID-19 Diagnostic and Management Protocol for Pediatric Patients Clinics (Sao Paulo). 2020;75:e1894. Published on-line 2020 Apr 13. doi: 10.6061/clinics/2020/e18941.
  6. Chen Z.M., Fu J.F., Shu Q., et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J. Pediatr. 2020. doi: 10.1007/ s12519-020-00345-5.
  7. Tang A., Xu W., Shen M., et al. One suggested reason is that children may be less susceptible to the infection as a result of possible differences in the expression of the angiotensin-converting enzyme 2 (ACE2). A retrospective study of the clinical characteristics of COVID-19 infection in 26 children. medRxiv. 2020. doi: 10.1101/2020.03.08.20029710.
  8. Dong Y., Mo X., Hu Y., et al. Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. Pediatr. 2020:pii e20200702. Doi: 10.1542/ peds.2020-0702.
  9. Lu X., Zhang L., Du H., et al. SARS-CoV-2 Infection in Children. N. Engl J. Med. 2020;382(17):1663-65. doi: 10.1056/NEJMc2005073.
  10. Molloy E.J., Bearer C.F. COVID-19 in children and altered inflammatory responses. Pediatr. Res. 2020;88(3):340-41. doi: 10.1038/s41390-020-0881-y.
  11. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J. Eur Acad Dermatol Venereol. 2020;34(5):e212-13. Doi: 10.1111/ jdv.16387.
  12. Joob B., Wiwanitkit V. COVID-19 can present with a rash and be mistaken for Dengue. J. Am Acad Dermatol. 2020:pii:S0190-9622(20)30454-0. doi: 10.1016/j.jaad.2020.03.036.
  13. Soldati G., Smargiassi A., Inchingolo R., et al. Is there a role for lung ultrasound during the COVID-19 pandemic? J. Ultrasound Med. 2020;39(7):1459- 62. Doi: 10.1002/ jum.15284.
  14. Bouadma L., Lescure F.X., Lucet J.C., et al. Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists. Intensive Care Med. 2020;46(4):579-82. doi: 10.1007/s00134-020-05967-x.
  15. Cai J., Xu J., Lin D., et al. A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. 2020:pii: ciaa198. doi: 10.1093/cid/ciaa198.
  16. Cao B., Wang Y., Wen D., et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N. Engl J. Med. 2020;382(19):1787-99. doi: 10.1056/NEJMoa2001282.
  17. COVID-19 у детей. Временные методические рекомендации. Правительство Москвы. Департамент здравоохранения города Москвы. Март 2020. 66 с.
  18. Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi: 10.1016/S0140-6736(20)30566-3.
  19. Zimmermann P., Curtis N. Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J. 2020. Doi: 10.1097/ INF.0000000000002660.
  20. Wang Y., Zhu L.Q. Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019. World J. Pediatr. 2020;16(3):271-274. Doi: 10.1007/ s12519-020-00353-5.
  21. Методические рекомендации. особенности клинических проявлений и лечения заболевания, вызванного новой коронавирусной инфекцией (COVID-19) у детей. Версия 2. (03.07.2020, утв. Минздравом России). 2000. 74 с.
  22. WHO Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance. V. 1.2. March 13 2020.
  23. Alder Hey Children's Hospital: Clinical Management Of Children Admitted to Hospital with COVID-19. March 2020. Version 1. URL: https://alderhey.nhs.uk/application/ files/1815/8422/1173/COVID_19_IN_ CHILDREN_CLINICAL_GUIDANCE_v1.pdf.
  24. URL: https://www.who.int/blueprint/priority-diseases/keyaction/Global_Research_Forum_ FINAL_VERSION_for_web_14_feb_2020. pdf?ua=1.
  25. Russell B., Moss C., Rigg A., Van Hemelrijck M. COVID-19 and Treatment With NSAIDs and Corticosteroids: Should We Be Limiting Their Use in the Clinical Setting? Ecancermedicalscience. 2020;14:1023. Doi: 10.3332/ ecancer.2020.1023.
  26. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) (Released by National Health Commission & State Administration of Traditional Chinese Medicine on March 3, 2020. URL: https://www.chinadaily. com.cn/pdf/2020/1.Clinical.Protocols.for.the. Diagnosis.and.Treatment.of.COVID-19.V7.pdf.
  27. Shen K., Yang Y., Wang T., et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement. World J. Pediatr. 2020;16(3):223-31. doi: 10.1007/s12519-020-00343-7.
  28. So C., Ro S., Murakami M., Imai R., Jinta T. High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series. Respirol Case Rep. 2020;8(6):e00596. Doi: 10.1002/ rcr2.596. Available at: https://www.ncbi.nlm. nih.gov/pubmed/32514354. Jun 4, 2020.
  29. Fadel R., Morrison A.R., Vahia A., et al. COVID-19 Management Task Force. Early Short Course Corticosteroids in Hospitalized Patients With COVID-19. Clin Infect Dis. 2020 May 19;ciaa601. doi: 10.1093/cid/ciaa601.
  30. URL: https://www.recoverytrial.net/files/ recovery_dexamethasone_statement_ 160620_ v2final.pdf.
  31. Liu W., Zhang Q., Chen J., et al. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. N Engl J Med. 2020;382(14):1370-71. doi: 10.1056/NEJMc2003717.
  32. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: https://www.covid19treatmentguidelines. nih.gov/ctevamxthasohes.
  33. Thachil J., Tang N., Gando S., et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-26. Doi:10.1111/ jth.14810.
  34. Thachil J. The versatile heparin in COVID-19. J Thromb Haemost. 2020;18(5):1020-22. doi: 10.1111/jth.14821
  35. Shen C., Wang Z., Zhao F., et al. Treatment of 5 critically ill patients with COVID 19 with convalescent plasma. JAMA. 2020;323(16):1582-89. Doi: 10.1001/ jama.2020.4783
  36. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet. Infect Dis. 2020;20(4):398-400. doi: 10.1016/S1473-3099(20)30141-9.
  37. Casadevall A, Pirofski L.A. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545-48. Doi: 10.1172/ JCI138003.
  38. Zhang B, Liu S., Tan T, et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest. 2020;158(1):e9e13. doi: 10.1016/j.chest.2020.03.039.
  39. Tanne J.K. COVID-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020;368:m1256. doi: 10.1136/bmj. m1256.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies